Cargando…

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety

PURPOSE: Randomized trials report that single-inhaler triple therapy is more effective than dual bronchodilators at reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, this effect may have been influenced by the forced withdrawal of inhaled corticosteroids...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suissa, Samy, Dell’Aniello, Sophie, Ernst, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440703/ https://www.ncbi.nlm.nih.gov/pubmed/36065315 http://dx.doi.org/10.2147/COPD.S378486

Ejemplares similares

Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study
por: Ernst, Pierre, et al.
Publicado: (2011)

Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality
por: Suissa, Samy, et al.
Publicado: (2012)

Pramipexole use and the risk of pneumonia
por: Ernst, Pierre, et al.
Publicado: (2012)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
por: Vogelmeier, Claus F., et al.
Publicado: (2022)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Cardiac glycosides use and the risk of lung cancer: a nested case–control study
por: Couraud, Sébastien, et al.
Publicado: (2014)

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
por: Kardos, Peter, et al.
Publicado: (2016)

Triple therapy in COPD: understanding the data
por: Suissa, Samy
Publicado: (2023)

Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study
por: Martinez, Carlos, et al.
Publicado: (2010)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
por: Huiart, L, et al.
Publicado: (2011)

A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case–control study
por: Azoulay, Laurent, et al.
Publicado: (2012)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Dual Bronchodilator in the Era of Triple Therapy
por: Papaioannou, Andriana I, et al.
Publicado: (2020)

The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
por: Dobler, Claudia C.
Publicado: (2018)

Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study
por: Loo, Simone Y, et al.
Publicado: (2018)

Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
por: Douros, Antonios, et al.
Publicado: (2018)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal
por: Yawn, Barbara P, et al.
Publicado: (2016)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
por: Juvelekian, Georges, et al.
Publicado: (2015)

Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
por: Neder, José Alberto, et al.
Publicado: (2019)

Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
por: Cheng, Shih-Lung, et al.
Publicado: (2017)

Beyond Dual Bronchodilation – Triple Therapy, When and Why
por: Cazzola, Mario, et al.
Publicado: (2022)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
por: Bateman, Eric D., et al.
Publicado: (2013)

"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2010)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Initial inhaler choice in COPD: real-world evidence
por: Jones, Thomas
Publicado: (2019)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jh947isaqklhjsj6c6auag3th9